G2GBIO Inc. (KOSDAQ:456160)

South Korea flag South Korea · Delayed Price · Currency is KRW
212,000
+15,600 (7.94%)
At close: Sep 17, 2025
7.94%
Market Cap1.26T
Revenuen/a
Net Incomen/a
Shares Out5.37M
EPSn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume592,169
Average Volume609,270
Open203,000
Previous Close196,400
Day's Range197,300 - 217,000
52-Week Range82,700 - 217,000
Betan/a
RSI80.88
Earnings Daten/a

About G2GBIO

G2GBIO Inc., a clinical-stage biotech company, provides pharmaceutical products. The company’s pipeline products includes GB-5001, GB-5001A, and GB-5112 for the treatment of alzheimer’s disease; GB-6002, an opioid drug that is used for post-operative pain treatment; GB-7001 for type-2 diabetes treatments; GB-5313 for the treatment of Osteoarthritis; GB-7101 and GB-7103 for the treatment of prostate cancer; GB-6201 and GB-6203 for androgenetic alopecia treatments; and GH-001 for the treatment of Hepatitis B. It also develops GB-2001 for animal c... [Read more]

Industry Pharmaceutical Preparations
Founded 2017
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 456160
Full Company Profile

News

There is no news available yet.